Alamar Biosciences, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Alamar Biosciences, Inc.'s yearly results, compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Tangible Assets Ratio: Of every $100 the company owns, $99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 86% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
—Data incomplete
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-25.5×Operating cash was negative last year, while some debt falls due within a year.
Lower than 60% of Healthcare companies in United States.
Cash Cushion Ratio
−1%Debt, after subtracting cash, equals 1% of its market value (net debt).
Lower than 68% of Healthcare companies in United States.
Tangible Assets Ratio
99%Of every $100 the company owns, $99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 86% of Healthcare companies in United States.
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Alamar Biosciences, Inc. made a loss over the last year. Alamar Biosciences, Inc. owes $0.20 for every $1 it owns. Alamar Biosciences, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossAlamar Biosciences, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
6.59The share price is 6.59 times Alamar Biosciences, Inc.'s book value per share, higher than 78% of Healthcare companies in United States.
Market cap
$2.1 BThe total market value of all of Alamar Biosciences, Inc.'s shares at today's price (share price × number of shares), larger than 75% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$313 MWhat Alamar Biosciences, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$4.51Net worth divided by the number of shares. The share price of $29.72 is 6.6 times this, which is the P/B above.
Owes vs Owns
0.20×Alamar Biosciences, Inc. owes $0.20 for every $1 it owns (low), lower than 72% of Healthcare companies in United States.
Dividend yield
NoneAlamar Biosciences, Inc. does not currently pay a dividend.
Revenue growth
+195%Revenue rose 195% in the year to Dec 2025.
Profit growth
LossAlamar Biosciences, Inc. made a loss in each of the last two years.
Profit margin
-40.2%Alamar Biosciences, Inc. lost $40 for every $100 of revenue.
Interest cover
Not coveredAlamar Biosciences, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net debtAlamar Biosciences, Inc. had $11 M more debt than cash (net debt) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Alamar Biosciences, Inc.: $2.1 B ÷ $313 M (30 Jun 2026) = 6.6.
How much does Alamar Biosciences, Inc. owe compared with what it owns?
Alamar Biosciences, Inc. owes $0.20 for every $1 it owns (low), lower than 72% of Healthcare companies in United States.
Does Alamar Biosciences, Inc. pay a dividend?
No. Alamar Biosciences, Inc. does not currently pay a dividend.
Is Alamar Biosciences, Inc.'s revenue growing?
Revenue rose 195% in the year to Dec 2025.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.